Multiple Sclerosis :: Update on Tysabri in multiple sclerosis patients

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that new data from the TOUCH Prescribing Program? and TYGRIS safety study confirm the safety profile from previous clinical studies of TYSABRI? (natalizumab). Also presented at the 59th annual meeting of the American Academy of Neurology in Boston, MA were extension study data that showed that TYSABRI has a sustained treatment effect on clinical relapses and the risk of disability progression in multiple sclerosis (MS) patients treated for up to three years.

Healthcare :: British Columbia joins with Canada’s Government to announce Patient Wait Times Guarantee

The Honourable Tony Clement, Federal Minister of Health, and the Honourable George Abbott, Minister of Health for British Columbia, announced that British Columbia will establish a Patient Wait Times Guarantee for radiation therapy by March 31, 2010, to be supported by $76.4 million in federal funding. British Columbia will also be eligible to benefit from the $400 million in new funding for Canada Health Infoway, and the $30 million for pilot projects as announced in Budget 2007.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack